Malvern Panalytical and Concept Life Sciences Launch Amplify Analytics

Article

The partnership combines Malvern’s physicochemical characterization expertise and Concept Life Sciences’ chemistry and analytical services to provide services that focus on analytics, know-how, instrumentation, and expert support to customers.

Malvern Panalytical, a scientific instrumentation provider located in Malvern, United Kingdom, and Concept Life Sciences, a contract research organization based in Cheshire, United Kingdom, announced the launch of Amplify Analytics, a new range of services designed to help pharmaceutical companies identify drug candidates that meet bioavailability and processability requirements, on June 25, 2020.

The partnership combines Malvern’s physicochemical characterization expertise and Concept Life Sciences’ chemistry and analytical services to provide services that focus on analytics, know-how, instrumentation, and expert support to customers, a Malvern press release said. The service will offer specific analytical capabilities and will work to provide third-party management of entire projects, through to deploying techniques, training, and data interpretation support.

“Amplify Analytics combines Concept Life Sciences’ expertise in discovery chemistry, API screening, and GMP manufacturing with Malvern Panalytical’s long-held knowledge and experience in applying physicochemical analysis to drug development,” said Dr. Paul Kippax, Pharmaceutical and Food Sector director at Malvern Panalytical, in the press release. “Within the pharmaceutical industry, an increased emphasis on return on investment and the application of continuous and additive manufacturing methods is pushing the desire to find small molecule drug candidates which easily fit development and scale-up capabilities-this can be unlocked and enabled by the application of physicochemical screening during early development.”

Source: Malvern

 

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content